Form 4: Alkermes Executive Trades Shares Under 10b5-1 Plan

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson, exercised stock options and sold ordinary shares, while also receiving new option and RSU awards, all under a pre-arranged 10b5-1 trading plan.

Summary

• EVP R&D, Chief Medical Officer Craig C. Hopkinson, engaged in multiple transactions involving Alkermes plc. ordinary shares and derivative securities.
• Exercised 5,000 employee stock options at an exercise price of $19.34 per share.
• Sold 9,000 ordinary shares at a weighted average price of $29.7206 per share, with prices ranging from $29.29 to $30.13.
• Acquired 83,037 new employee stock options with an exercise price of $30.25 per share, which will vest in four equal annual installments commencing March 2, 2027.
• Received an award of 38,568 Restricted Stock Units (RSUs), which will vest in four equal annual installments commencing March 2, 2027.
• All option exercises and sales were conducted under a Rule 10b5-1 trading plan adopted on March 14, 2025.
• Following these transactions, Hopkinson directly beneficially owns 89,389 ordinary shares, 104,393 employee stock options (21,356 fully vested, 83,037 vesting annually), and 38,568 Restricted Stock Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and portfolio management under a pre-arranged plan, with new equity awards balancing out a share sale.

Positives

• Insider received new equity awards (83,037 stock options and 38,568 RSUs), indicating continued alignment with company performance and long-term incentives.
• The transactions were pre-planned under a Rule 10b5-1 plan, suggesting a structured and non-opportunistic approach to managing personal holdings.

Negatives

• Insider sold 9,000 ordinary shares, which could be perceived as a reduction in direct equity exposure, although this is partially offset by new equity awards.

Future Outlook

The filing details future vesting schedules for newly granted stock options and Restricted Stock Units, with vesting commencing on March 2, 2027, and continuing in four equal annual installments.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as a means for executives to manage their equity holdings systematically and diversify their portfolios. These plans help mitigate concerns about opportunistic trading and are a standard component of executive compensation.

Stakeholder Impact

• Shareholders: May view the sale of shares as a slight reduction in insider ownership, but the acquisition of new options and RSUs, coupled with the Rule 10b5-1 plan, provides context that these are routine compensation and portfolio management activities, likely resulting in minimal overall impact.

Next Steps

• Vesting of 83,037 employee stock options in four equal annual installments, commencing March 2, 2027.
• Vesting of 38,568 Restricted Stock Units in four equal annual installments, commencing March 2, 2027.

Key Dates

Recommendation

The filing details routine insider transactions, including both sales and new equity awards, executed under a pre-arranged 10b5-1 plan. These actions do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as investors should rely on broader company fundamentals rather than these standard insider activities.

Keywords

Alkermes, ALKS, Form 4, insider trading, stock options, RSU, Rule 10b5-1, executive compensation, beneficial ownership